# Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV Melanoma

> **NCT00010309** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Genzyme, a Sanofi Company**

## Conditions studied

- Melanoma (Skin)

## Interventions

- **BIOLOGICAL:** MART-1 antigen
- **BIOLOGICAL:** gp100 antigen

## Key facts

- **NCT ID:** NCT00010309
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2000-11
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2014-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00010309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00010309, "Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV Melanoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00010309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*